Videos

Ferhina S. Ali, MD, MPH, discusses the management of progressive geographic atrophy in an 84-year-old man, focusing on the significance of patient education in optimizing treatment outcomes and adherence.

Ferhina S. Ali, MD, MPH, discusses management and treatment considerations for an 89-year-old woman with dry age-related macular degeneration (AMD) and geographic atrophy (GA), emphasizing the importance of monitoring for choroidal neovascularization and addressing the patient’s progressive vision loss.

Ferhina S. Ali, MD, MPH, discusses how to effectively manage geographic atrophy by considering treatment timing, utilizing imaging modalities, analyzing phase 3 trial data, and developing personalized treatment algorithms based on disease severity while highlighting the encouraging compliance of patients undergoing long-term therapies.

Fasika Woreta, MD, spoke about shattering glass ceilings in ophthalmology, highlighting the importance of diversity, mentorship, and empowering women in leadership roles within the field during her WIO Honorary Lecture and Award.

Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care.

The final case is presented by Dr Adam, showcasing a 79-year old patient with multiple diagnoses and rapid progression of geographic atrophy.

A second case is examined by Dr Adam, examining a 79-year old diagnosed with cataracts and geographic atrophy.

Dr Adam introduces a patient case for a 70-year old patient being treated with a specific case of geographic atrophy.

Murtaza Adam, MD, opens a discussion surrounding complement therapies for patients diagnosed with geographic atrophy.

A Retina expert discusses approaches for treating geographic atrophy in patients who also have neovascular AMD, presenting specific patient cases and providing key insights for successfully managing such cases.

Carl D. Regillo, MD, FACS, FASRS presents a case study of a patient with bilateral geographic atrophy, discussing the decision-making process for determining which eye to treat first, considering factors such as the extent of atrophy and vision in each eye.

An expert retina specialist discusses the recent FDA-approved treatments for geographic atrophy (GA) that slow disease progression and highlights key factors to consider before starting treatment.

Carl D. Regillo, MD, FACS, FASRS, discusses geographic atrophy, the advanced stage of dry age-related macular degeneration, including its diagnosis, and progression.

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Amitha Domalpally, MD, PhD, discusses how disorganization of retinal inner layers affects OCT outcomes in cases of uveitic macular edema.

Philip P. Storey, MD, shares the highlights of his ARVO presentation on a post hoc analysis of the pivotal TENAYA/LUCERNE trials.

Experts conclude the series with the hope that longer-acting agents will lead to better real-world outcomes for patients, mirroring clinical trial results and potentially preventing vision loss, especially in countries with limited access to healthcare.

Experts discusses concerns related to the use of new agents, focusing on intraocular inflammation (IOI) and potential batch variations in biologics faricimab and aflibercept. He emphasizes close monitoring for IOI and advises clinicians to scrutinize patients for any signs of inflammation during follow-up visits.

Peter Kaiser, MD shares his early experiences with faricimab and high dose aflibercept for nAMD and DME. He notes positive outcomes, especially with hard-to-treat patients, and emphasizes the ongoing evaluation of patient response to treatment.

Peter Kaiser, MD discusses the utilization of newer agents, faricimab and high dose aflibercept, for refractory patients who haven't responded well to previous treatments and for patients doing well but aiming to extend dosing intervals.

Experts discuss the use of steroids, particularly in the context of diabetic macular edema (DME). The inflammatory nature of DME reveals the effectiveness of steroids, especially in cases where persistent fluid remains despite anti-VEGF treatment.

David Eichenbaum, MD, FASRS concludes this series with the final case of a treatment-experienced patient switching from aflibercept 2 mg to high-dose aflibercept 8 mg with noticeable improvement after the first dose.